The failure last week of Biogen Inc. BIIB -4.48% and Eisai Co.’s ESALY 6.19% once-promising Alzheimer’s disease drug was the latest in a spate of disappointments for medicines designed to target Beta amyloid, a sticky substance long known to accumulate in the brains of people with the disease.

Continue Reading at the Wall Street Journal >